
Cigna Commercial Membership Clinical Guidelines
For Cigna Medicare membership guidelines click here.
Supplemental Information
Comprehensive Musculoskeletal Management Guidelines
- Interventional Pain Management Quick Reference Guide Guideline
- Joint Surgery Quick Reference Guide Guideline
- Preface to the Comprehensive Musculoskeletal Guidelines
- Preface to the Comprehensive Musculoskeletal Guidelines - Effective 12/18/2025
Interventional Pain and Joint Surgery
- Ablations/Denervations of Facet Joints and Peripheral Nerves (CMM-208) Guideline - Effective 12/18/2025
- Ablations/Denervations of Facet Joints and Peripheral Nerves (CMM-208) Guideline
- Epidural Adhesiolysis (CMM-207) Guideline
- Epidural Steroid Injections (CMM-200) Guideline
- Facet Joint Injections/Medial Branch Blocks (CMM-201) Guideline
- Hip Replacement/Arthroplasty (CMM-313) Guideline
- Hip Surgery Arthroscopic and Open Procedures (CMM-314) Guideline
- Implantable Intrathecal Drug Delivery System (CMM-210) Guideline
- Knee Replacement Arthroplasty (CMM-311) Guideline
- Knee Surgery - Arthroscopic and Open Procedures (CMM-312) Guideline
- Prolotherapy (CMM-204) Guideline
- Regional Sympathetic Blocks (CMM-209) Guideline
- Sacroiliac Joint Procedures (CMM-203) Guideline
- Shoulder Arthroplasty/Replacement/Resurfacing/Revision/Arthrodesis (CMM-318) Guideline
- Shoulder Surgery Arthroscopic and Open Procedures (CMM-315) Guideline
- Spinal Cord and Dorsal Root Ganglion Stimulation (CMM-211) Guideline
Spine Surgery
- Ablations/Denervations of Facet Joints and Peripheral Nerves (CMM-208) Guideline - Effective 12/18/2025
- Ablations/Denervations of Facet Joints and Peripheral Nerves (CMM-208) Guideline
- Anterior Cervical Discectomy and Fusion (CMM-601) Guideline
- Cervical Microdiscectomy (CMM-605) Guideline
- Cervical Total Disc Arthroplasty (CMM-602) Guideline
- Discography (CMM-401) Guideline
- Electrical and Low Frequency US Bone Growth Stimulation Spine (CMM-615) Guideline - Effective 12/18/2025
- Electrical and Low Frequency US Bone Growth Stimulation Spine (CMM-615) Guideline
- Grafts (CMM-612) Guideline
- Grafts (CMM-612) Guideline - Effective 12/18/2025
- Intradiscal Procedures (CMM-308) Guideline
- Intradiscal Procedures (CMM-308) Guideline - Effective 12/18/2025
- Lumbar Decompression (CMM-608) Guideline
- Lumbar Fusion (Arthrodesis) (CMM-609) Guideline
- Lumbar Microdiscectomy (Laminotomy, Laminectomy, or Hemilaminectomy) (CMM-606) Guideline
- Lumbar Total Disc Arthroplasty (CMM-610) Guideline
- Posterior Cervical Decompression (Laminectomy/ Hemilaminectomy/ Laminoplasty)(CMM-603) Guideline
- Posterior Cervical Fusion (CMM-604) Guideline
- Preface to Spine Surgery (CMM-600) Guideline
- Primary Vertebral Augmentation (Percutaneous Vertebroplasty-Kyphoplasty) and Sacroplasty (CMM-607) Guideline
- Sacroiliac Joint Fusion or Stabilization (CMM-611) Guideline
- Thoracic and Thoracolumbar Fusion (Arthrodesis) (CMM-614) Guideline
- Thoracic Decompression and Discectomy (CMM-613) Guideline
- Vertebral Body Tethering for Adolescent Idiopathic Scoliosis (CMM-616) Guideline
Gastrointestinal Endoscopic Procedure Guidelines
High-Tech Imaging and Cardiology Guidelines
- 2024 CPT 75580 Addendum to Cardiology & Radiology Imaging Guidelines
- Preface to the Imaging Guidelines
- Site of Care: High-tech Radiology
General
- Abdomen Imaging Guidelines
- Breast Imaging Guidelines - Effective 11/18/2025
- Breast Imaging Guidelines - Effective 12/01/2025
- Breast Imaging Guidelines
- Cardiac Imaging Guidelines
- Cardiac Imaging Guidelines - Effective 10/01/2025
- Chest Imaging Guidelines
- Head Imaging Guidelines
- Musculoskeletal Imaging Guidelines
- Neck Imaging Guidelines
- Oncology Imaging Guidelines - Effective 12/01/2025
- Oncology Imaging Guidelines
- Pelvis Imaging Guidelines
- Peripheral Nerve and Neuromuscular Disorders (PNND) Imaging Guidelines
- Peripheral Vascular Disease (PVD) Imaging Guidelines
- Spine Imaging Guidelines
Pediatric
- Pediatric Abdomen Imaging Guidelines
- Pediatric and Special Populations Oncology Imaging Guidelines
- Pediatric and Special Populations Spine Imaging Guidelines
- Pediatric Cardiac Imaging Guidelines
- Pediatric Chest Imaging Guidelines
- Pediatric Head Imaging Guidelines
- Pediatric Musculoskeletal Imaging Guidelines
- Pediatric Neck Imaging Guidelines
- Pediatric Pelvis Imaging Guidelines
- Pediatric Peripheral Nerve and Neuromuscular Disorder (PNND) Imaging Guidelines
- Pediatric Peripheral Vascular Disease (PVD) Imaging Guidelines
Peripheral Vascular Intervention
Laboratory Management - Molecular
- Cigna Lab Management Guidelines
- Cigna Lab Management Guidelines - Effective 01/01/2026
- Lab Management Prior Authorization CPT Code List - Effective 10/01/2025
- Lab Management Prior Authorization CPT Code List
Administrative
- MOL.AD.107.A: Unique Test Identifiers for Non-Specific Procedure Codes - Effective 01/01/2026
- MOL.AD.107.A: Unique Test Identifiers for Non-Specific Procedure Codes
- MOL.AD.304.A: Medical Necessity Review Information Requirements - Effective 01/01/2026
- MOL.AD.304.A: Medical Necessity Review Information Requirements
- MOL.AD.314.A: Date of Service and Authorization Period Effective Date - Effective 01/01/2026
- MOL.AD.314.A: Date of Service and Authorization Period Effective Date
- MOL.AD.364.A: Special Circumstances Influencing Coverage Determinations - Effective 01/01/2026
- MOL.AD.364.A: Special Circumstances Influencing Coverage Determinations
- MOL.AD.412.A: Laboratory Billing and Reimbursement - Effective 01/01/2026
- MOL.AD.412.A: Laboratory Billing and Reimbursement
Clinical Use
- MOL.CU.109.A: Genetic Testing for Cancer Susceptibility and Hereditary Cancer Syndromes - Effective 01/01/2026
- MOL.CU.109.A: Genetic Testing for Cancer Susceptibility and Hereditary Cancer Syndromes
- MOL.CU.110.A: Genetic Testing for Carrier Status - Effective 01/01/2026
- MOL.CU.110.A: Genetic Testing for Carrier Status
- MOL.CU.111.A: Genetic Testing for Non-Medical Purposes - Effective 01/01/2026
- MOL.CU.111.A: Genetic Testing for Non-Medical Purposes
- MOL.CU.112.A: Genetic Testing for Prenatal Screening and Diagnostic Testing - Effective 01/01/2026
- MOL.CU.112.A: Genetic Testing for Prenatal Screening and Diagnostic Testing
- MOL.CU.113.A: Genetic Testing for the Screening, Diagnosis, and Monitoring of Cancer - Effective 01/01/2026
- MOL.CU.113.A: Genetic Testing for the Screening, Diagnosis, and Monitoring of Cancer
- MOL.CU.114.A: Genetic Testing to Diagnose Non-Cancer Conditions - Effective 01/01/2026
- MOL.CU.114.A: Genetic Testing to Diagnose Non-Cancer Conditions
- MOL.CU.115.A: Genetic Testing to Predict Disease Risk - Effective 01/01/2026
- MOL.CU.115.A: Genetic Testing to Predict Disease Risk
- MOL.CU.116.A: Genetic Testing by Multigene Panels
- MOL.CU.116.A: Genetic Testing by Multigene Panels - Effective 01/01/2026
- MOL.CU.117.A: Experimental, Investigational, or Unproven Laboratory Testing
- MOL.CU.117.A: Experimental, Investigational, or Unproven Laboratory Testing - Effective 01/01/2026
- MOL.CU.118.A: Pharmacogenomic Testing for Drug Toxicity and Response
- MOL.CU.118.A: Pharmacogenomic Testing for Drug Toxicity and Response - Effective 01/01/2026
- MOL.CU.119.A: Preimplantation Genetic Screening and Diagnosis
- MOL.CU.119.A: Preimplantation Genetic Screening and Diagnosis - Effective 01/01/2026
- MOL.CU.246.A: Hereditary (Germline) Testing After Tumor (Somatic) Testing
- MOL.CU.246.A: Hereditary (Germline) Testing After Tumor (Somatic) Testing - Effective 01/01/2026
- MOL.CU.256.A: Confirmatory Genetic Testing
- MOL.CU.256.A: Confirmatory Genetic Testing - Effective 01/01/2026
- MOL.CU.291.A: Genetic Testing for Known Familial Mutations
- MOL.CU.291.A: Genetic Testing for Known Familial Mutations - Effective 01/01/2026
- MOL.CU.292.A: Genetic Testing for Variants of Uncertain Clinical Significance
- MOL.CU.292.A: Genetic Testing for Variants of Uncertain Clinical Significance - Effective 01/01/2026
- MOL.CU.333.B: Medically Necessary Laboratory Testing
- MOL.CU.333.B: Medically Necessary Laboratory Testing - Effective 01/01/2026
Test Specific
- MOL.TS.124.A: Alpha-1 Antitrypsin Deficiency Testing
- MOL.TS.124.A: Alpha-1 Antitrypsin Deficiency Testing - Effective 01/01/2026
- MOL.TS.125.A: Amyotrophic Lateral Sclerosis (ALS) Genetic Testing
- MOL.TS.125.A: Amyotrophic Lateral Sclerosis (ALS) Genetic Testing - Effective 01/01/2026
- MOL.TS.126.A: Angelman Syndrome Genetic Testing - Effective 01/01/2026
- MOL.TS.126.A: Angelman Syndrome Genetic Testing
- MOL.TS.129.A: Ashkenazi Jewish Carrier Screening
- MOL.TS.129.A: Ashkenazi Jewish Carrier Screening - Effective 01/01/2026
- MOL.TS.130.A: Ataxia-Telangiectasia Genetic Testing
- MOL.TS.144.A: CADASIL Genetic Testing - Effective 01/01/2026
- MOL.TS.144.A: CADASIL Genetic Testing
- MOL.TS.148.A: Charcot-Marie-Tooth Neuropathy Genetic Testing
- MOL.TS.148.A: Charcot-Marie-Tooth Neuropathy Genetic Testing - Effective 01/01/2026
- MOL.TS.150.A: Chromosomal Microarray Testing For Developmental Disorders (Prenatal and Postnatal)
- MOL.TS.150.A: Chromosomal Microarray Testing For Developmental Disorders (Prenatal and Postnatal) - Effective 01/01/2026
- MOL.TS.158.A: Cystic Fibrosis Genetic Testing
- MOL.TS.158.A: Cystic Fibrosis Genetic Testing - Effective 01/01/2026
- MOL.TS.162.A: Early Onset Familial Alzheimer Disease Genetic Testing
- MOL.TS.162.A: Early Onset Familial Alzheimer Disease Genetic Testing - Effective 01/01/2026
- MOL.TS.165.C Carrier Screening Panels, Including Targeted, Pan-Ethnic, Universal, and Expanded
- MOL.TS.165.C: Carrier Screening Panels, Including Targeted, Pan-Ethnic, Universal, and Expanded - Effective 01/01/2026
- MOL.TS.168.A: Familial Adenomatous Polyposis Genetic Testing - Effective 01/01/2026
- MOL.TS.168.A: Familial Adenomatous Polyposis Genetic Testing
- MOL.TS.169.A: Familial Hypercholesterolemia Genetic Testing
- MOL.TS.169.A: Familial Hypercholesterolemia Genetic Testing - Effective 01/01/2026
- MOL.TS.170.A: Familial Malignant Melanoma Genetic Testing
- MOL.TS.170.A: Familial Malignant Melanoma Genetic Testing - Effective 01/01/2026
- MOL.TS.182.A: Hereditary Cancer Syndrome Multigene Panels
- MOL.TS.182.A: Hereditary Cancer Syndrome Multigene Panels - Effective 01/01/2026
- MOL.TS.183.A: HFE Hemochromatosis Genetic Testing
- MOL.TS.183.A: HFE Hemochromatosis Genetic Testing - Effective 01/01/2026
- MOL.TS.193.A: Li-Fraumeni Syndrome Genetic Testing
- MOL.TS.193.A: Li-Fraumeni Syndrome Genetic Testing - Effective 01/01/2026
- MOL.TS.194.A: Liquid Biopsy Testing
- MOL.TS.194.A: Liquid Biopsy Testing - Effective 01/01/2026
- MOL.TS.197.A: Lynch Syndrome Genetic Testing
- MOL.TS.197.A: Lynch Syndrome Genetic Testing - Effective 01/01/2026
- MOL.TS.202.A: Marfan Syndrome Genetic Testing
- MOL.TS.206.A: MUTYH Associated Polyposis Genetic Testing - Effective 01/01/2026
- MOL.TS.206.A: MUTYH Associated Polyposis Genetic Testing
- MOL.TS.209.A: Non-Invasive Prenatal Screening
- MOL.TS.209.A: Non-Invasive Prenatal Screening - Effective 01/01/2026
- MOL.TS.215.A: PCA3 Testing for Prostate Cancer - Effective 01/01/2026
- MOL.TS.215.A: PCA3 Testing for Prostate Cancer
- MOL.TS.217.A: Prader-Willi Syndrome Genetic Testing - Effective 01/01/2026
- MOL.TS.217.A: Prader-Willi Syndrome Genetic Testing
- MOL.TS.223.A: PTEN Hamartoma Tumor Syndromes Genetic Testing
- MOL.TS.223.A: PTEN Hamartoma Tumor Syndromes Genetic Testing - Effective 01/01/2026
- MOL.TS.225.A: Spinal Muscular Atrophy Genetic Testing - Effective 01/01/2026
- MOL.TS.225.A: Spinal Muscular Atrophy Genetic Testing
- MOL.TS.227.A: Thoracic Aortic Aneurysms and Dissections (TAAD) Panel Genetic Testing
- MOL.TS.228.A: Tissue of Origin Testing for Cancer of Unknown Primary
- MOL.TS.228.A: Tissue of Origin Testing for Cancer of Unknown Primary - Effective 01/01/2026
- MOL.TS.230.C: Somatic Mutation Testing
- MOL.TS.230.C: Somatic Mutation Testing - Effective 01/01/2026
- MOL.TS.232.A: VeriStrat Testing for NSCLC TKI Response
- MOL.TS.235.C: Exome Sequencing - Effective 01/01/2026
- MOL.TS.235.C: Exome Sequencing
- MOL.TS.238.A: BRCA Analysis - Effective 01/01/2026
- MOL.TS.238.A: BRCA Analysis
- MOL.TS.248.A: Breast Cancer Index for Breast Cancer Prognosis - Effective 01/01/2026
- MOL.TS.248.A: Breast Cancer Index for Breast Cancer Prognosis
- MOL.TS.251.A: PALB2 Genetic Testing for Breast Cancer Risk
- MOL.TS.251.A: PALB2 Genetic Testing for Cancer Risk - Effective 01/01/2026
- MOL.TS.254.A: DecisionDX Uveal Melanoma - Effective 01/01/2026
- MOL.TS.254.A: DecisionDX Uveal Melanoma
- MOL.TS.257.A: Epilepsy Genetic Testing - Effective 01/01/2026
- MOL.TS.257.A: Epilepsy Genetic Testing
- MOL.TS.258.A: Maturity-Onset Diabetes of the Young (MODY) Genetic Testing
- MOL.TS.258.A: Maturity-Onset Diabetes of the Young Genetic Testing - Effective 01/01/2026
- MOL.TS.266.A: Mitochondrial Disorders Genetic Testing
- MOL.TS.266.A: Mitochondrial Disorders Genetic Testing - Effective 01/01/2026
- MOL.TS.267.A: Ehlers-Danlos Syndrome Genetic Testing
- MOL.TS.268.A: Hereditary Connective Tissue Disorder Genetic Testing
- MOL.TS.269.A: Autism, Intellectual Disability, and Developmental Delay Genetic Testing
- MOL.TS.269.A: Autism, Intellectual Disability, and Developmental Delay Genetic Testing - Effective 01/01/2026
- MOL.TS.271.A: PancraGEN
- MOL.TS.273.A: Nonsyndromic Hearing Loss and Deafness Genetic Testing - Effective 01/01/2026
- MOL.TS.273.A: Nonsyndromic Hearing Loss and Deafness Genetic Testing
- MOL.TS.276.A: Polymerase Gamma (POLG) Related Disorders Genetic Testing - Effective 01/01/2026
- MOL.TS.276.A: Polymerase Gamma (POLG) Related Disorders Genetic Testing
- MOL.TS.282.A: DermTech Melanoma Test - Effective 01/01/2026
- MOL.TS.282.A: DermTech Pigmented Lesion Assay
- MOL.TS.287.A: Hereditary Pancreatitis Genetic Testing
- MOL.TS.287.A: Hereditary Pancreatitis Genetic Testing - Effective 01/01/2026
- MOL.TS.288.A: Limb-Girdle Muscular Dystrophy Genetic Testing - Effective 01/01/2026
- MOL.TS.288.A: Limb-Girdle Muscular Dystrophy Genetic Testing
- MOL.TS.290.A: Facioscapulohumeral Muscular Dystrophy Genetic Testing - Effective 01/01/2026
- MOL.TS.290.A: Facioscapulohumeral Muscular Dystrophy Genetic Testing
- MOL.TS.294.A: Decipher Prostate Cancer Classifier
- MOL.TS.294.A: Decipher Prostate Cancer Classifier - Effective 01/01/2026
- MOL.TS.295.A: Genomic Prostate Score - Effective 01/01/2026
- MOL.TS.297.A: Prolaris - Effective 01/01/2026
- MOL.TS.301.A: Neurofibromatosis Type 1 Genetic Testing
- MOL.TS.301.A: Neurofibromatosis Type 1 Genetic Testing - Effective 01/01/2026
- MOL.TS.302.A: Legius Syndrome Genetic Testing - Effective 01/01/2026
- MOL.TS.302.A: Legius Syndrome Genetic Testing
- MOL.TS.306.C: Genome Sequencing
- MOL.TS.306.C: Genome Sequencing - Effective 01/01/2026
- MOL.TS.307.A: AlloSure for Kidney Transplant Rejection - Effective 01/01/2026
- MOL.TS.307.A: AlloSure for Kidney Transplant Rejection
- MOL.TS.309.A: Friedreich Ataxia Genetic Testing
- MOL.TS.310.A: Hereditary Ataxia Multigene Panel Testing
- MOL.TS.311.A: Spinocerebellar Ataxia Genetic Testing
- MOL.TS.324.A: CHARGE Syndrome and CHD7 Disorder Genetic Testing - Effective 01/01/2026
- MOL.TS.324.A: CHARGE Syndrome and CHD7 Disorder Genetic Testing (previously CHARGE Syndrome Genetic Testing)
- MOL.TS.344.A: Chromosomal Microarray for Solid Tumors
- MOL.TS.344.A: Chromosomal Microarray for Solid Tumors - Effective 01/01/2026
- MOL.TS.359.A: Inflammatory Bowel Disease Biomarker Testing - Effective 01/01/2026
- MOL.TS.359.A: Inflammatory Bowel Disease Biomarker Testing
- MOL.TS.360.A: Inherited Bone Marrow Failure Syndrome (IBMFS) Testing
- MOL.TS.360.A: Inherited Bone Marrow Failure Syndrome (IBMFS) Testing - Effective 01/01/2026
- MOL.TS.361.A: Human Platelet and Red Blood Cell Antigen Genotyping
- MOL.TS.361.A: Human Platelet and Red Blood Cell Antigen Genotyping - Effective 01/01/2026
- MOL.TS.371.A: Noonan Spectrum Disorder Genetic Testing
- MOL.TS.371.A: Noonan Spectrum Disorder Genetic Testing - Effective 01/01/2026
- MOL.TS.396.A: Multi-Cancer Early Detection Screening
- MOL.TS.396.A: Multi-Cancer Early Detection Screening - Effective 01/01/2026
- MOL.TS.410.A: Cardiomyopathy and Arrhythmia Genetic Testing - Effective 01/01/2026
- MOL.TS.410.A: Cardiomyopathy and Arrhythmia Genetic Testing
- MOL.TS.419.A: Primary Ciliary Dyskinesia Genetic Testing
- MOL.TS.419.A: Primary Ciliary Dyskinesia Genetic Testing - Effective 01/01/2026
- MOL.TS.425.A: Hereditary Ataxia Genetic Testing - Effective 01/01/2026
- MOL.TS.427.A: Hereditary Connective Tissue and Thoracic Aortic Disease Genetic Testing - Effective 01/01/2026
- MOL.TS.482.C: Carrier Screening Panels, Including Targeted, Pan-Ethnic, Universal, and Expanded - Effective 01/01/2026
Radiation & Medical Oncology Guidelines
Medical Oncology
Radiation Oncology
Physician Worksheets
- Adrenal Cancer Physician Worksheet
- Anal Canal Cancer Worksheet
- Bile Duct Cancer Physician Worksheet
- Bladder Cancer Physician Worksheet
- Bone Metastases - Xofigo Physician worksheet
- Bone Metastases Physician Worksheet
- Brain Metastases Physician Worksheet
- Breast Cancer Physician Worksheet
- Central Nervous (CNS) Lymphoma Physician Worksheet
- Central Nervous (CNS) Neoplasm Physician Worksheet
- Cervical Cancer Physician Worksheet
- Endometrial Cancer Physician Worksheet
- Esophageal Cancer Physician Worksheet
- Extracranial Oligometastases Physician Worksheet
- Gallbladder Cancer Physician Worksheet
- Gastric (Stomach) Cancer Physician Worksheet
- Head and Neck Cancer Physician Worksheet
- Hepatobiliary Cancer Physician Worksheet
- Hodgkin's Lymphoma Physician Worksheet
- Hyperthermia Physician Worksheet
- Kidney Cancer Physician Worksheet
- Liver Cancer Physician Worksheet
- Liver Cancer, Selective Internal Radiation Therapy Physician Worksheet
- Lung Cancer, Small Cell Physician Worksheet
- Multiple Myeloma Cancer Physician Worksheet
- Non-Cancerous Diagnosis Physician Worksheet
- Non-Hodgkin's Lymphoma Physician Worksheet
- Non-Small Cell Lung Cancer Physician Worksheet
- Other Cancer Type Physician Worksheet
- Other Metastases (non-Bone/Brain) Physician Worksheet
- Pancreatic Cancer Physician Worksheet
- Prophylactic Cranial Irradiation (PCI) Radiation Therapy Physician Worksheet
- Prophylactic Cranial Irradiation (PCI) Radiation Therapy Physician Worksheet
- Prostate Cancer Physician Worksheet
- Radiopharmaceuticals Physician Worksheet
- Rectal Cancer Physician Worksheet
- Skin Cancer Physician Worksheet
- Soft Tissue Sarcoma Physician Worksheet
- Testicular Cancer Physician Worksheet
- Ureter/Urethral Cancer Physician Worksheet
- Vulva Cancer Physician Worksheet
Sleep Clinical Guidelines
Additional Information
Other Cigna guidelines and policies that may be relevant are available on the Cigna website.
For questions or comments regarding EviCore's Guidelines
EviCore's clinical guidelines are evidence-based and apply to the following categories of service for individuals with Cigna-administered plans:
- Computed Tomography (CT) and Computed Tomography Angiography (CTA)
- Magnetic Resonance Imaging (MRI) and Magnetic Resonance Angiography (MRA)
- Positron Emission Tomography (PET)
- Nuclear Cardiology
- Cardiac Stress Echocardiography
- Diagnostic Cardiac Catheterization
- Pain Management
- Major Joint Surgery
- Radiation Therapy (Oncology)
The terms of an individual's particular coverage plan document [Group Service Agreement (GSA), Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD), or similar plan document] may differ significantly from the standard coverage plans upon which these guidelines are based. If these clinical guidelines are inconsistent with the terms of the individual's specific coverage plan, then the terms of the individual's coverage plan always takes precedence.
Coverage determinations in each specific instance require consideration of:
- The terms of the applicable coverage plan document in effect on the date of service
- Any applicable laws or regulations
- Any relevant collateral source materials including clinical guidelines
- The specific facts of the particular situation
EviCore's guidelines are based upon major national and international association and society guidelines and criteria, peer-reviewed literature, major treatises, and input from health plans, practicing academic and community-based physicians.
Medical technology is continuously evolving; the guidelines undergo a formal review annually, however EviCore reserves the right to change and update the guidelines without prior notice. Additional clinical guidelines may be developed as needed or may be withdrawn from use.
These guidelines are not intended to supersede or replace sound medical judgment, but instead should facilitate the identification of the most appropriate imaging procedure given the individual's clinical condition. These guidelines are written to cover medical conditions as experienced by the majority of individuals. However, these guidelines may not be applicable in certain clinical circumstances. EviCore's clinical guidelines may include information inapplicable to benefit plans administered by Cigna.
Clinical decisions, including treatment decisions, are the responsibility of the individual and his/her provider. Clinicians are expected to use independent medical judgment which takes into account the clinical circumstances to make individual management decisions.
EviCore supports the work of physicians and others who strive to reduce the overuse of diagnostic tests that are of low value, of no value, or where the risks of a given diagnostic test are greater than the benefits.
All material on this website is, unless otherwise stated, the property of EviCore healthcare. ALL RIGHTS RESERVED. Copyright and other intellectual property laws protect these materials. Reproduction or retransmission of the materials, in whole or in part, in any manner, without the prior written consent of the copyright holder, is a violation of copyright law. By using this site, you acknowledge that this material is copyrighted and agree to the terms and conditions noted above.